Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations

Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Kimito Kawahata

Research output: Contribution to journalArticle

Abstract

Objective: To study maintenance therapy after achievement of the lowest possible disease activity in systemic lupus erythematosus (SLE) without major organ manifestations. Methods: We retrospectively evaluated patients with SLE who visited our hospital from Jan 2015 to Feb 2018 and were taking prednisolone (PSL) < 10 mg/day. After excluding those with neuropsychiatric SLE or severe lupus nephritis, patients were divided into four groups according to their maintenance monotherapy treatment, namely, prednisolone (PSL), immunosuppressant (IS), hydroxychloroquine (HCQ), and no drugs. The groups were then compared with regard to cumulative flare rate and changes in SLE Disease Activity Index (SLEDAI). Results: There were 47 patients on PSL, 10 on IS, 5 on HCQ, and 11 on no drugs. Flare rate was higher in the no drug group, and no patients with the IS or HCQ group experienced a flare (p = 0.003). A reduction in SLEDAI was only seen in the IS and HCQ groups (p = 0.05 and p = 0.03, respectively). There were no differences in adverse events among groups during the study period. Conclusions: Our results suggest that the cessation of all drugs is associated with disease flare for SLE patients without major organ manifestations. IS or HCQ monotherapy might be a reasonable maintenance strategy comparing with steroid monotherapy.Key Point• Immunosuppressant or hydroxychloroquine monotherapy appears to be a reasonable maintenance strategy.

Original languageEnglish
JournalClinical Rheumatology
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

Hydroxychloroquine
Immunosuppressive Agents
Systemic Lupus Erythematosus
Glucocorticoids
Prednisolone
Maintenance
Pharmaceutical Preparations
Therapeutics
Central Nervous System Lupus Vasculitis
Lupus Nephritis
Steroids

Keywords

  • Hydroxychloroquine
  • Immunosuppressive agents
  • Relapse
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. / Hanaoka, Hironari; Iida, Harunobu; Kiyokawa, Tomofumi; Takakuwa, Yukiko; Kawahata, Kimito.

In: Clinical Rheumatology, 01.01.2019.

Research output: Contribution to journalArticle

@article{e0191949a60443a280d7fc0f80d24908,
title = "Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations",
abstract = "Objective: To study maintenance therapy after achievement of the lowest possible disease activity in systemic lupus erythematosus (SLE) without major organ manifestations. Methods: We retrospectively evaluated patients with SLE who visited our hospital from Jan 2015 to Feb 2018 and were taking prednisolone (PSL) < 10 mg/day. After excluding those with neuropsychiatric SLE or severe lupus nephritis, patients were divided into four groups according to their maintenance monotherapy treatment, namely, prednisolone (PSL), immunosuppressant (IS), hydroxychloroquine (HCQ), and no drugs. The groups were then compared with regard to cumulative flare rate and changes in SLE Disease Activity Index (SLEDAI). Results: There were 47 patients on PSL, 10 on IS, 5 on HCQ, and 11 on no drugs. Flare rate was higher in the no drug group, and no patients with the IS or HCQ group experienced a flare (p = 0.003). A reduction in SLEDAI was only seen in the IS and HCQ groups (p = 0.05 and p = 0.03, respectively). There were no differences in adverse events among groups during the study period. Conclusions: Our results suggest that the cessation of all drugs is associated with disease flare for SLE patients without major organ manifestations. IS or HCQ monotherapy might be a reasonable maintenance strategy comparing with steroid monotherapy.Key Point• Immunosuppressant or hydroxychloroquine monotherapy appears to be a reasonable maintenance strategy.",
keywords = "Hydroxychloroquine, Immunosuppressive agents, Relapse, Systemic lupus erythematosus",
author = "Hironari Hanaoka and Harunobu Iida and Tomofumi Kiyokawa and Yukiko Takakuwa and Kimito Kawahata",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10067-019-04633-y",
language = "English",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations

AU - Hanaoka, Hironari

AU - Iida, Harunobu

AU - Kiyokawa, Tomofumi

AU - Takakuwa, Yukiko

AU - Kawahata, Kimito

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To study maintenance therapy after achievement of the lowest possible disease activity in systemic lupus erythematosus (SLE) without major organ manifestations. Methods: We retrospectively evaluated patients with SLE who visited our hospital from Jan 2015 to Feb 2018 and were taking prednisolone (PSL) < 10 mg/day. After excluding those with neuropsychiatric SLE or severe lupus nephritis, patients were divided into four groups according to their maintenance monotherapy treatment, namely, prednisolone (PSL), immunosuppressant (IS), hydroxychloroquine (HCQ), and no drugs. The groups were then compared with regard to cumulative flare rate and changes in SLE Disease Activity Index (SLEDAI). Results: There were 47 patients on PSL, 10 on IS, 5 on HCQ, and 11 on no drugs. Flare rate was higher in the no drug group, and no patients with the IS or HCQ group experienced a flare (p = 0.003). A reduction in SLEDAI was only seen in the IS and HCQ groups (p = 0.05 and p = 0.03, respectively). There were no differences in adverse events among groups during the study period. Conclusions: Our results suggest that the cessation of all drugs is associated with disease flare for SLE patients without major organ manifestations. IS or HCQ monotherapy might be a reasonable maintenance strategy comparing with steroid monotherapy.Key Point• Immunosuppressant or hydroxychloroquine monotherapy appears to be a reasonable maintenance strategy.

AB - Objective: To study maintenance therapy after achievement of the lowest possible disease activity in systemic lupus erythematosus (SLE) without major organ manifestations. Methods: We retrospectively evaluated patients with SLE who visited our hospital from Jan 2015 to Feb 2018 and were taking prednisolone (PSL) < 10 mg/day. After excluding those with neuropsychiatric SLE or severe lupus nephritis, patients were divided into four groups according to their maintenance monotherapy treatment, namely, prednisolone (PSL), immunosuppressant (IS), hydroxychloroquine (HCQ), and no drugs. The groups were then compared with regard to cumulative flare rate and changes in SLE Disease Activity Index (SLEDAI). Results: There were 47 patients on PSL, 10 on IS, 5 on HCQ, and 11 on no drugs. Flare rate was higher in the no drug group, and no patients with the IS or HCQ group experienced a flare (p = 0.003). A reduction in SLEDAI was only seen in the IS and HCQ groups (p = 0.05 and p = 0.03, respectively). There were no differences in adverse events among groups during the study period. Conclusions: Our results suggest that the cessation of all drugs is associated with disease flare for SLE patients without major organ manifestations. IS or HCQ monotherapy might be a reasonable maintenance strategy comparing with steroid monotherapy.Key Point• Immunosuppressant or hydroxychloroquine monotherapy appears to be a reasonable maintenance strategy.

KW - Hydroxychloroquine

KW - Immunosuppressive agents

KW - Relapse

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85067056577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067056577&partnerID=8YFLogxK

U2 - 10.1007/s10067-019-04633-y

DO - 10.1007/s10067-019-04633-y

M3 - Article

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -